Identification of an element within the promoter of human selenoprotein P responsive to transforming growth factor-beta.

Selenoprotein P (SeP) is a plasma protein that contains up to 10 selenocysteine residues and accounts for about 50% of total selenium in human plasma. We have previously shown that SeP expression in the human liver cell line HepG2 is inhibited by transforming growth factor (TGF)-beta1 on a transcriptional level. Smad proteins are the transcriptional mediators of TGF-beta signalling and putative Smad-binding elements (SBE) comprising the core sequence CAGACA are present at two positions in the SeP promoter. The aim of our study was to investigate whether Smad molecules are involved in inhibition of SeP expression by TGF-beta1 and to locate the promoter region critical for this effect. As seen in electrophoretic-mobility-shift assays, TGF-beta1 treatment led to enhanced binding of nuclear proteins to a putative SBE from the SeP promoter. Overexpression of Smad 3 and 4, but not of Smad 2, resulted in a marked down-regulation of SeP mRNA expression. Similar effects were observed for luciferase expression under control of a human SeP-promoter construct. Deletion as well as point-mutation of putative SBEs led to a loss of promoter sensitivity towards TGF-beta1 treatment. Hence, we demonstrated an involvement of Smad 3 and 4 in transcriptional regulation of SeP by TGF-beta1 and we were able to identify the TGF-beta-responsive element in the SeP promoter.

Modulation of selenoprotein P expression by TGF-beta(1) is mediated by Smad proteins.

Selenoprotein P (SeP) is a selenium-rich plasma protein which accounts for more than 50% this study, the effect of TGF-beta(1) on the expression of SeP in the human liver cell line HepG2 was investigated. Western analysis revealed a dose-dependent reduction of SeP content in cell supernatant. RT-PCR analysis of SeP-mRNA expression demonstrated a marked inhibition and a reporter gene under control of the SeP promoter was negatively regulated by TGF-beta(1). Smad proteins are the transcriptional mediators of TGF-beta signaling. A putative Smad-binding element (SBE) is present in the SeP promoter. In electrophoretic-mobility-shift assays, TGF-beta(1) enhanced the binding of nuclear proteins to this SBE. Overexpression of Smad3 and 4 resulted in a downregulation of SeP-promoter activity whereas deletion of the SBE led to a loss of TGF-beta(1) responsiveness. We conclude that SeP expression is modulated by the binding of Smad3/4 complexes to a functional SBE in the SeP promoter.

The influence of the cytokines Il-1beta and INFgamma on the expression of selenoproteins in the human hepatocarcinoma cell line HepG2.

Metabolic labeling of HepG2 cells with 75selenite indicated the expression of more than four selenoproteins in the 80 to 45 kDa range and more than four selenoproteins in the 24 to 14 kDa range. Although there were no significant changes in the total protein content, determined by the method of BioRad, the densitometric analysis of the autoradiogramms showed a reduced expression of all labeled selenoproteins in the cell lysates of HepG2 after cytokine treatment for 24 hours. A stronger reduction was observed after treatment with Il-1beta than with IFNgamma. Moreover, the inhibitory effects were more significant for those selenoproteins in the higher molecular mass range. Our data on the inhibition of selenoprotein synthesis and on repression of SeP promoter activity show that the expression of selenoproteins, especially of SeP, is influenced by acute phase reaction and pro-inflammatory reactions.

Transforming growth factor-beta1 inhibits expression of selenoprotein P in cultured human liver cells.

The effect of cytokines on the expression of selenoprotein P (SeP) in the human liver cell line HepG2 was investigated. Treatment with interleukin-1beta, interferon-gamma, and tumor necrosis factor-alpha had no effect on SeP levels in culture media or on SeP mRNA expression. Conversely, Western analysis revealed a dose-dependent reduction of SeP content in culture medium after treatment with transforming growth factor (TGF)-beta1 with an 1C50 of 31 pM. Treatment with 100 pM TGF-51 for 48 h led to a decrease to 21 +/- 9% of controls. RT-PCR analysis of SeP mRNA expression demonstrated an inhibition of SeP transcription to 40+/-2% of control levels after 24 h. The expression of a luciferase reporter construct under control of the human SeP promoter was downregulated by TGF-beta1 treatment in a dose-dependent fashion indicating a transcriptional regulation of the SeP gene by TGF-beta1.

[Expert assessment of medical treatment errors--a new responsibility for the medical service of health insurance]. / Die Begutachtung ärztlicher Behandlungsfehler--eine neue Aufgabe für den Medizinischen Dienst der Krankenversicherung (MDK).

During the past few years there has been an enormous increase of inquiries for medical certificates concerning suspected mistakes in medical treatment (medical malpractice). The profound changes of the social circumstances and the social law (e.g. section 66 SGB V) are responsible for this situation. The legal involvement of the "Gesetzliche Krankenversicherung" (GKV) and the "Medizinischer Dienst der Krankenversicherung" (MDK) into social legislation concerning the expert opinion are mentioned. The general development of the judgement of medical malpractice and its legal background, which bases on the contract between doctor and patient, is shown. As a practical example serves the description of the procedure of judging medical malpractice in the MDK. First statistical results, which have been developed since summer 1997 in Hamburg are presented. Some interesting tendencies are obvious: orthopedics and surgery are involved with more than 50%. "Characteristic mistakes in therapy" are the most important question for the expert opinion. Creating a medical certificate concerning medical malpractice takes about 6-12 weeks. This tendency is decreasing because of fast learning procedures, caused by the increasing demand of expert opinions. The medical judgement of medical malpractice will become one of the main tasks of the medical service in health insurance. The "MDK's" have to adapt to this change in tasks in medical, legal and organisation-technical respect, if they want to offer competent and up to date judgement in future times.

Selenoproteins are expressed in fetal human osteoblast-like cells.

Selenoproteins are involved in mechanisms of cell differentiation and defense. We investigated the expression of glutathione peroxidases, as well as other selenoproteins, in fetal human osteoblasts (hFOB-cells). Using 75-selenium metabolic labelling of viable hFOB-cells, we identified several selenoproteins in cell lysates of about 45-80 kDa and in the migration range of 14 kDa to 24 kDa. Cells expressed low mRNA levels of both cellular glutathione peroxidase and plasma glutathione peroxidase mRNA as analysed by Southern analysis of RT-PCR products. Basal cellular glutathione peroxidase enzyme activity in hFOB-cells (19.7 nmol NADPH oxidised per min and microg protein) was further increased 2.5-fold by the addition of 100 nM sodium selenite to the culture medium for 3 days. Furthermore, expression of selenoprotein P mRNA was demonstrated by RT-PCR. hFOB-cells did not show activities of the selenoproteins type I or type II 5'-deiodinase. In summary, we identified cellular glutathione peroxidase, plasma glutathione peroxidase and selenoprotein P among of a panel of several 75-selenium labelled proteins in human fetal osteoblasts. The expression of selenoproteins like glutathione peroxidases in hFOB-cells represents a new system of osteoblast antioxidative defense that may be relevant for the protection against hydrogen peroxide produced by osteoclasts during bone remodelling.

Expression pattern of gastrointestinal selenoproteins--targets for selenium supplementation.

There is experimental and epidemiological evidence for an association between low selenium levels and gastrointestinal cancer incidence, prevalence, and mortality. To identify targets for selenium supplementation in the human digestive tract, we examined mRNA expression of various selenocysteine-containing proteins in normal mucosa biopsy specimens. Tissue samples from the esophagus and from different sites of the stomach, small bowel, and colon were obtained during endoscopies of the upper and lower gastrointestinal tract. Northern blot analyses revealed a lack of cytosolic glutathione peroxidase mRNA but a differential mRNA expression pattern of gastrointestinal and plasma glutathione peroxidase, selenoprotein P, and thioredoxin reductase. Glutathione peroxidase and thioredoxin reductase activities were detected in the mucosa of all biopsies, but the differential pattern did not reflect the differential mRNA steady-state levels. In addition to gastrointestinal glutathione peroxidase, which was found to play a role in colon cancer resistance, we identified further gastrointestinal selenoproteins, which may be involved in gastrointestinal cell defense and cell differentiation.

Cloning and characterization of the human selenoprotein P promoter. Response of selenoprotein P expression to cytokines in liver cells.

We isolated an 18-kilobase (kb) genomic selenoprotein P clone from a human placenta library and cloned, sequenced, and characterized the 5'-flanking region of the human selenoprotein P gene. Sequence analysis revealed an intron between base pairs (bp) -13 and -14 upstream of the ATG codon and another one between bp 534 and 535 of the coding region. The major transcription start site of selenoprotein P in human HepG2 hepatocarcinoma cells was mapped to bp -70 by 5'-rapid amplification of cDNA ends and by primer extension. 1.8 kb of the 5'-flanking sequence were fused to a luciferase reporter gene. They exhibited functional promoter activity in HepG2 hepatocarcinoma and Caco2 colon carcinoma cells in transient transfection experiments. Treatment of transfected HepG2 cells with the cytokines interleukin 1beta, tumor necrosis factor alpha, and interferon gamma repressed promoter activity. Nuclear extracts of interferon gamma-treated cells bound to a signal transducer and activator of transcription response element of the promoter in gel retardation experiments. By transfection of promoter-deletion constructs, a TATA box and a putative SP1 site were identified to be necessary for selenoprotein P transcription. These data indicate that the human selenoprotein P gene contains a strong promoter that is cytokine responsive. Furthermore, selenoprotein P, secreted by the liver, might react as a negative acute phase protein.

Expression of selenoproteins in various rat and human tissues and cell lines.

Various rat and human tissues and cell lines naturally exposed to endogenous or exogenous oxidative stress were examined for their pattern of selenoprotein transcripts. Selenoprotein P mRNA was mainly expressed in rat kidney, testis, liver and lung. In testis, a high phospholipid hydroperoxide glutathione peroxidase (PHGPx) but only a weak cytosolic glutathione peroxidase (cGPx) signal was obtained. In kidney, spleen, heart, liver and lung cGPx mRNA levels were higher than those of PHGPx and for both only weak signals were obtained with brain mRNA. The Northern blot results concerning the tissue distribution of cGPx in the rat were fully supported by activity measurements. None of the human tissues revealed a PHGPx mRNA signal, whereas selenoprotein P transcripts were present in all human tissues with the highest abundance in heart, liver, and lung, tissues which also exhibited strong cGPx signals. The gastrointestinal glutathione peroxidase (GPx-GI) was only expressed in human liver and colon liver. Liver, the organ that showed the broadest repertoire of selenoproteins, has to cope with reactive oxygen intermediates produced during detoxification reactions. Human cell lines of the myeloic system that may be exposed to oxidative stress during inflammatory processes showed distinct cGPx signals: epithelial cells showed low cGPx signals. Similar cGPx mRNA levels were found in normal human thyroid tissue and thyroid carcinoma cells. Among the human cell lines selenoprotein P expression was detected in HepG2 and HTh74 thyroid cells. Our data confirm the necessity of getting specific information on distinct tissue- and cell-specific patterns of selenoprotein expression as endpoints of selenium supply and biological function of the selenoprotein family. Analysis of total selenium contents of tissues or body fluids only provides integrative information on the global selenium status of individuals.

[Selenoproteins in bone, gastrointestinal tract and thyroid gland of the human]. / Selenoproteine im Knochen, Gastrointestinaltrakt und in der Schilddrüse des Menschen.

BASIS: Selenium is an essential trace element, which is incorporated as selenocysteine (secys) into specific proteins in a regulated fashion. In the presence of a hairpin loop structure within the 3' untranslated region of the mRNA the opal stop codon UGA is coding for selenocysteine. Selenoprotein functions are dependent on secys incorporation. Members of the family of deiodinases as well as the family of glutathione peroxidases, selenoprotein P and thioredoxin reductase are selenoproteins. DISCUSSION: Bone, the intestine and the thyroid rely on antioxidant systems against potential cell and DNA damage through endogenous and environmental peroxides and reactive oxygen species (ROS) potentially promoting inflammation and tumorigenesis. Optimized cell defense through antioxidant selenoproteins requires optimal selenium supplementation of the organism. We have analyzed the expression of selenoproteins in these tissues, thus providing molecular tools to further elucidate optimal selenium supply on a cellular level. CONCLUSION: Clinical intervention studies that focus on the development of disease must confirm the relevance of optimized selenium supply for the pathogenesis, prevention and therapy of metabolic bone disease as well as chronic (autoimmune) inflammation and tumorigenesis in the thyroid and intestine.